Aerie Pharmaceuticals Financial Statements (AERI)
|
|
Report date
|
|
|
01.03.2018 |
01.03.2019 |
24.02.2020 |
26.02.2021 |
25.02.2022 |
|
04.11.2022 |
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
0.000 |
24.2 |
69.9 |
83.1 |
194.1 |
|
213.9 |
Operating Income, bln rub |
|
|
-145.7 |
-209.7 |
-187.5 |
-155.7 |
-45.3 |
|
-23.2 |
EBITDA, bln rub |
? |
|
-143.1 |
-227.6 |
-166.3 |
-117.2 |
-7.81 |
|
-3.07 |
Net profit, bln rub |
? |
|
-145.1 |
-232.6 |
-199.6 |
-183.1 |
-74.8 |
|
-36.6 |
|
OCF, bln rub |
? |
|
-93.2 |
-152.6 |
-150.4 |
-64.7 |
-99.2 |
|
7.17 |
CAPEX, bln rub |
? |
|
16.0 |
31.3 |
9.96 |
3.10 |
3.29 |
|
4.53 |
FCF, bln rub |
? |
|
-109.2 |
-183.9 |
-160.4 |
-67.8 |
-102.4 |
|
2.64 |
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
OPEX, bln rub |
|
|
145.7 |
233.3 |
252.5 |
213.5 |
213.6 |
|
217.1 |
Cost of production, bln rub |
|
|
0.000 |
0.641 |
4.83 |
25.3 |
26.8 |
|
23.5 |
R&D, bln rub |
|
|
72.1 |
86.1 |
91.4 |
74.0 |
75.8 |
|
87.6 |
Interest expenses, bln rub |
|
|
2.37 |
2.53 |
15.3 |
26.5 |
28.9 |
|
12.0 |
|
Assets, bln rub |
|
|
290.3 |
285.0 |
452.6 |
402.0 |
431.4 |
|
375.6 |
Net Assets, bln rub |
? |
|
135.6 |
227.8 |
167.0 |
24.0 |
-17.3 |
|
-164.0 |
Debt, bln rub |
|
|
123.8 |
0.000 |
194.2 |
215.3 |
260.6 |
|
337.0 |
Cash, bln rub |
|
|
249.7 |
202.8 |
309.2 |
240.4 |
139.8 |
|
172.5 |
Net debt, bln rub |
|
|
-125.8 |
-202.8 |
-115.0 |
-25.1 |
120.8 |
|
164.5 |
|
Ordinary share price, rub |
|
|
59.8 |
36.1 |
24.2 |
13.5 |
7.02 |
|
15.2 |
Number of ordinary shares, mln |
|
|
35.3 |
41.7 |
45.4 |
45.9 |
46.3 |
|
47.8 |
|
Market cap, bln rub |
|
|
2 111 |
1 504 |
1 098 |
620 |
325 |
|
728 |
EV, bln rub |
? |
|
1 985 |
1 301 |
983 |
595 |
446 |
|
893 |
Book value, bln rub |
|
|
136 |
228 |
167 |
24 |
-17 |
|
-164 |
|
EPS, rub |
? |
|
-4.11 |
-5.58 |
-4.39 |
-3.99 |
-1.61 |
|
-0.76 |
FCF/share, rub |
|
|
-3.09 |
-4.41 |
-3.53 |
-1.48 |
-2.21 |
|
0.06 |
BV/share, rub |
|
|
3.84 |
5.47 |
3.68 |
0.52 |
-0.37 |
|
-3.43 |
|
EBITDA margin, % |
? |
|
|
-941.2% |
-238.0% |
-141.0% |
-4.02% |
|
-1.44% |
Net margin, % |
? |
|
|
-961.8% |
-285.6% |
-220.2% |
-38.5% |
|
-17.1% |
FCF yield, % |
? |
|
-5.17% |
-12.2% |
-14.6% |
-10.9% |
-31.5% |
|
0.36% |
ROE, % |
? |
|
-107.0% |
-102.1% |
-119.5% |
-763.9% |
431.6% |
|
22.3% |
ROA, % |
? |
|
-50.0% |
-81.6% |
-44.1% |
-45.5% |
-17.3% |
|
-9.73% |
|
P/E |
? |
|
-14.5 |
-6.47 |
-5.50 |
-3.39 |
-4.35 |
|
-19.9 |
P/FCF |
|
|
-19.3 |
-8.18 |
-6.85 |
-9.15 |
-3.18 |
|
276.2 |
P/S |
? |
|
|
62.2 |
15.7 |
7.46 |
1.68 |
|
3.40 |
P/BV |
? |
|
15.6 |
6.60 |
6.58 |
25.9 |
-18.8 |
|
-4.44 |
EV/EBITDA |
? |
|
-13.9 |
-5.72 |
-5.91 |
-5.08 |
-57.1 |
|
-290.4 |
Debt/EBITDA |
|
|
0.88 |
0.89 |
0.69 |
0.21 |
-15.5 |
|
-53.5 |
|
R&D/CAPEX, % |
|
|
451.3% |
275.0% |
917.6% |
2 387% |
2 304% |
|
1 933% |
|
CAPEX/Revenue, % |
|
|
|
129.5% |
14.2% |
3.73% |
1.70% |
|
2.12% |
|
Aerie Pharmaceuticals shareholders |